Because of the encouraging results from these clinical trials, osimertinib became the first third-generation EGFR-TKI to receive approval for the clinical application for NSCLC patients with EGFR T790M mutation [19–21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.